Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Profit After Tax (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Profit After Tax for 3 consecutive years, with -$10.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Profit After Tax fell 176.63% year-over-year to -$10.2 million, compared with a TTM value of -$19.1 million through Dec 2024, down 470.25%, and an annual FY2024 reading of -$19.1 million, down 474.61% over the prior year.
  • Profit After Tax was -$10.2 million for Q4 2024 at Oramed Pharmaceuticals, up from -$19.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $13.3 million in Q4 2023 and bottomed at -$19.6 million in Q3 2024.
  • Average Profit After Tax over 3 years is -$4.6 million, with a median of -$5.3 million recorded in 2022.
  • Peak annual rise in Profit After Tax hit 701.96% in 2024, while the deepest fall reached 508.91% in 2024.
  • Year by year, Profit After Tax stood at -$12.3 million in 2022, then skyrocketed by 208.49% to $13.3 million in 2023, then crashed by 176.63% to -$10.2 million in 2024.
  • Business Quant data shows Profit After Tax for ORMP at -$10.2 million in Q4 2024, -$19.6 million in Q3 2024, and $9.2 million in Q2 2024.